What is Innovative Medtech Inc's earnings per share (EPS)?

Innovative Medtech Inc (IMTH) reported diluted earnings per share of $0.03 for fiscal year 2025. This represents a 109.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Innovative Medtech Inc Financials

IMTH

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE June

This page shows Innovative Medtech Inc (IMTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMTH FY2025 2026-04-22

Balance-sheet repair, not operating momentum, dominates the picture as liabilities shrink while the company remains severely cash-constrained.

From FY2024 to FY2025, total liabilities fell from $6.1M to $1.3M. But liquidity did not heal: FY2025 ended with just $13.6K of cash and $250K of total assets, pointing to a balance-sheet cleanup rather than an operating recovery that rebuilt financial capacity.

When revenue was last reported in FY2024, the company produced $1.8M of sales against an operating loss of $4.0M, so the cost structure was far larger than the revenue base could support. That usually means survival depends more on financing or liability restructuring than on the core operation funding itself.

Before the FY2025 reset, operating cash outflow narrowed from -$582.9K in FY2022 to -$183.1K in FY2024, so cash burn was improving even while accounting losses remained heavy. Lower burn helped, but working-capital coverage still fell to 0.0x in FY2025, which means the business did not build a usable liquidity cushion.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Innovative Medtech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Innovative Medtech Inc's current ratio of 0.02 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.03

YoY+109.1%

Innovative Medtech Inc earned $0.03 per diluted share (EPS) in fiscal year 2025. This represents an increase of 109.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$14K

YoY+1459.7%

5Y CAGR+77.8%

10Y CAGR+12.2%

Innovative Medtech Inc held $14K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

54M

YoY+124.9%

Innovative Medtech Inc had 54M shares outstanding in fiscal year 2025. This represents an increase of 124.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

IMTH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$1.8M+5.8%	$1.7M+32.9%	$1.3M+271.7%	$349K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$360K+1364.6%	$25K-97.5%	$973K+4.2%	$933K+215.9%	$295K	N/A
Operating Income	N/A	-$4.0M-10.5%	-$3.6M+80.1%	-$18.3M-2475.6%	-$709K	N/A
Interest Expense	$85K-2.9%	$87K-43.6%	$155K-15.1%	$183K+5.9%	$172K	N/A
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	N/A	-$7.9M-117.6%	-$3.6M+79.8%	-$18.1M-453.1%	-$3.3M	N/A
EPS (Diluted)	$0.03+109.1%	$-0.33	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	$428K-6.1%	$456K+0.3%	$455K+5.2%	$433K-10.0%	$481K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	$17K-84.9%	$115K+127.1%	-$426K-294.7%	$219K+3902.8%	$5K-97.6%	$226K
Operating Income	N/A	-$57K+94.7%	-$1.1M-29.9%	-$827K+71.5%	-$2.9M-234.9%	-$865K-822.0%	-$94K+36.1%	-$147K
Interest Expense	N/A	$42K+41.9%	$30K+1.2%	$30K+20.4%	$25K-19.9%	$31K+196.5%	$10K-52.7%	$22K
Income Tax	N/A	$0	$0	N/A	N/A	$0	$0	N/A
Net Income	N/A	-$89K+92.1%	-$1.1M-27.3%	-$884K	N/A	-$910K-383.6%	-$188K-14.0%	-$165K
EPS (Diluted)	N/A	$0.00+100.0%	$-0.04	N/A	N/A	$-0.04-300.0%	$-0.01	N/A

IMTH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$250K-61.6%	$652K-85.3%	$4.4M-7.3%	$4.8M-6.5%	$5.1M+669925.7%	$766
Current Assets	$23K-91.9%	$284K-27.9%	$394K-23.5%	$515K-22.3%	$663K+86417.2%	$766
Cash & Equivalents	$14K+1459.7%	$873-22.1%	$1K-99.6%	$301K-30.5%	$433K+56484.2%	$766
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$161K-28.3%	$225K+20.6%	$186K+4.3%	$179K	$0
Goodwill	N/A	$0-100.0%	$178K0.0%	$178K-94.7%	$3.4M	$0
Total Liabilities	$1.3M-78.8%	$6.1M+6.5%	$5.8M-7.3%	$6.2M+19.7%	$5.2M+28.4%	$4.0M
Current Liabilities	$1.3M-68.2%	$4.1M+14.7%	$3.6M-7.2%	$3.9M+38.0%	$2.8M-30.9%	$4.0M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$14K-92.8%	$201K
Total Equity	-$1.1M+80.8%	-$5.5M-319.1%	-$1.3M+7.2%	-$1.4M-2443.9%	-$55K+98.6%	-$4.0M
Retained Earnings	-$43.3M+2.8%	-$44.6M-21.7%	-$36.6M-11.1%	-$33.0M-121.1%	-$14.9M-28.0%	-$11.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$250K-76.4%	$1.1M-6.1%	$1.1M-11.5%	$1.3M+96.2%	$652K-86.0%	$4.7M+7.6%	$4.3M-5.3%	$4.6M
Current Assets	$23K-90.9%	$250K-5.8%	$266K-26.0%	$359K+26.6%	$284K-58.7%	$688K+130.4%	$298K-39.4%	$492K
Cash & Equivalents	$14K+3779.2%	$351+258.2%	$98-99.9%	$174K+19864.8%	$873+42.4%	$613+6.1%	$578-99.8%	$257K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	N/A	N/A	$166K+3.4%	$161K-27.0%	$221K+12.7%	$196K-12.9%	$225K
Goodwill	N/A	N/A	N/A	N/A	$0-100.0%	$178K0.0%	$178K0.0%	$178K
Total Liabilities	$1.3M-78.1%	$6.0M-0.4%	$6.0M-5.2%	$6.3M+2.8%	$6.1M+1.6%	$6.0M+1.1%	$6.0M-0.9%	$6.0M
Current Liabilities	$1.3M-67.5%	$4.0M+0.6%	$4.0M-6.5%	$4.3M+4.1%	$4.1M+3.9%	$3.9M+3.8%	$3.8M-0.6%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.1M+78.5%	-$4.9M-1.0%	-$4.8M+3.6%	-$5.0M+8.3%	-$5.5M-298.3%	-$1.4M+16.0%	-$1.6M-13.0%	-$1.5M
Retained Earnings	-$43.3M+7.2%	-$46.7M-0.2%	-$46.6M-2.5%	-$45.4M-2.0%	-$44.6M-17.6%	-$37.9M-2.5%	-$37.0M-0.5%	-$36.8M

IMTH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$183K-8.4%	-$169K+71.0%	-$583K-2174.3%	$28K	N/A
Capital Expenditures	N/A	$51K+302.4%	$13K-72.8%	$46K	N/A	N/A
Free Cash Flow	N/A	-$234K-28.8%	-$182K+71.1%	-$629K	N/A	N/A
Investing Cash Flow	N/A	-$51K-1037.9%	$5K+153.0%	-$10K+99.3%	-$1.6M	$0
Financing Cash Flow	N/A	$190K+857.1%	$20K-95.7%	$461K-76.6%	$2.0M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	N/A	-$18K+83.3%	-$106K-444.5%	$31K-40.4%	$52K+409.6%	-$17K+90.9%	-$183K-420.1%	-$35K
Capital Expenditures	N/A	N/A	N/A	$12K+125.9%	-$45K	$0	$0-100.0%	$95K
Free Cash Flow	N/A	N/A	N/A	$19K+166.3%	$7K+143.3%	-$17K+90.9%	-$183K-40.3%	-$130K
Investing Cash Flow	N/A	N/A	N/A	-$12K-125.9%	$45K	$0	$0+100.0%	-$95K
Financing Cash Flow	N/A	N/A	$77K+86.5%	$41K+5694.7%	$716-98.2%	$39K+149.0%	-$79K-134.6%	$229K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMTH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-219.4%-9.3pp	-210.1%+1196.9pp	-1407.0%-1204.0pp	-203.0%	N/A
Net Margin	N/A	-435.0%-223.5pp	-211.5%+1180.2pp	-1391.7%-456.5pp	-935.1%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-1217.8%-1135.9pp	-82.0%+294.2pp	-376.2%-312.6pp	-63.6%	N/A
Current Ratio	0.02-0.1	0.07-0.0	0.11-0.0	0.13-0.1	0.24+0.2	0.00
Debt-to-Equity	-1.24-0.1	-1.12+3.3	-4.40-4.4	0.00+0.3	-0.26-0.2	-0.05
FCF Margin	N/A	-12.8%-2.3pp	-10.5%+38.0pp	-48.5%	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-193.0%+441.9pp	-634.9%-444.9pp	-190.1%-168.4pp	-21.7%+8.8pp	-30.5%
Net Margin	N/A	N/A	N/A	-206.3%	N/A	-199.9%-156.4pp	-43.5%-9.1pp	-34.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-8.3%+91.0pp	-99.3%-30.2pp	-69.1%	N/A	-19.5%-15.2pp	-4.3%-0.7pp	-3.6%
Current Ratio	0.02-0.0	0.060.0	0.07-0.0	0.08+0.0	0.07-0.1	0.17+0.1	0.08-0.1	0.13
Debt-to-Equity	-1.24-0.0	-1.22+0.0	-1.23+0.0	-1.25	N/A	-4.38-0.7	-3.64+0.5	-4.15
FCF Margin	N/A	N/A	N/A	4.5%+2.9pp	1.6%+5.3pp	-3.7%+38.6pp	-42.3%-15.2pp	-27.1%

Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cardiac Biotech Solutions Inc CBSC

$5.0M

Encision ECIA

$3.4M

Reflect Scientfc RSCF

$4.0M

Standard Dental Labs Inc TUTH

$4.2M

United Health Pr UEEC

$15.5M

Frequently Asked Questions

What are Innovative Medtech Inc's total assets?

Innovative Medtech Inc (IMTH) had $250K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Innovative Medtech Inc have outstanding?

Innovative Medtech Inc (IMTH) had 54M shares outstanding as of fiscal year 2025.

What is Innovative Medtech Inc's current ratio?

Innovative Medtech Inc (IMTH) had a current ratio of 0.02 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Innovative Medtech Inc's debt-to-equity ratio?

Innovative Medtech Inc (IMTH) had a debt-to-equity ratio of -1.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Innovative Medtech Inc's debt-to-equity ratio negative or unusual?

Innovative Medtech Inc (IMTH) has negative shareholder equity of -$1.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Innovative Medtech Inc?

Innovative Medtech Inc (IMTH) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.